Disease Landscape and Forecast Insights

Colorectal cancer (CRC) affects several thousands of people in Brazil and Mexico. Once it metastasizes, the only available therapeutic options are premium-priced targeted agents and chemotherapy…

The U.S. rheumatoid arthritis (RA) market is crowded, with the availability of nine different biologics and Xeljanz, representing six distinct drug classes. With the impending entry of biosimilars…

The regulatory and market access environment for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, staying ahead of the similarities and…

The U.S. asthma therapy market has long been dominated by several effective and well-established treatments, including inhaled and oral therapies, but following the recent approval of two biologics…

The prevalence of spondyloarthritis is increasing in China, where the estimated number of total prevalent cases of ankylosing spondylitis (AS) exceeds 1.6 million. Although the total prevalence of…

Introduction Rheumatoid arthritis (RA) affects a significant percentage of Argentinian and Mexican populations and often requires the use of premium-priced biologics. Rheumatologists have…

Introduction:The prevalence of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in Brazil and Mexico is estimated at 1.3 million and is expected to keep growing. The entry of biosimilars…

Introduction Rheumatoid arthritis (RA) is a chronic disease that affects more than 1 million Brazilians and often requires the use of premium-priced therapies. The coverage of these drugs is…

Introduction Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as…

Introduction Rheumatoid arthritis (RA) represents a lucrative market, particularly because of the entrenched positioning of biologics in the treatment algorithm. A number of RA biologics have…

Biologics prescribed by rheumatologists and gastroenterologists are among the most commercially successful biopharmaceutical products in the world. These biologics are a prime target for biosimilar…

Physician and Payer Perspectives on Biologic Use and Novel Therapeutic Targets in the Treatment of Psoriatic Arthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis…